Only 3 out of 5 heart failure patients see cardiologist at least once a year: Study
New Delhi: Only around three out of five heart failure patients see a cardiologist at least once a year, according to new research released on Sunday.
The study, published in the European Heart Journal, shows that patients who do see a cardiologist once a year are around 24 per cent less likely to die in the following year.
It also shows which patients could benefit from seeing a cardiologist once a year and which patients should be seen more often. The research suggests that if cardiologists did see heart failure patients at least once a year, one life could be saved for every 11–16 patients seen.
'In patients with heart failure, the heart is unable to normalise blood flow and pressure. Heart failure can't usually be cured, but with the right treatment, symptoms can often be controlled for many years. At the moment, depending on the patient and their condition, for example whether they have chronic or acute heart failure, they may or may not be seen by a cardiologist,' said Dr Guillaume Baudry from the Clinical Investigation Centre of Nancy University Hospital in France.
The study included all French patients living with heart failure in January 2020 who had been diagnosed in the previous five years -- 655,919 people in total.
These patients were found using French national medical administrative data. Researchers broke the group down according to whether they had been hospitalised with heart failure in the last year or the last five years, and whether or not they were taking diuretics as a treatment.
Diuretics help the body eliminate excess sodium through urine, which reduces the build-up of fluid in the body.
Among all groups of patients, researchers found that around two out of every five patients did not see a cardiologist over the course of a year.
Those who did see a cardiologist were less likely to die of any cause and less likely to be hospitalised with heart failure in the following year.
For patients who had been hospitalised in the last year, four appointments with a cardiologist were optimal. This reduced the risk from 34.3 per cent to 18.2 per cent, according to the study.
Dr Baudry said: 'Although there are inherent limitations in observational research, our findings highlight the potential value of specialist follow-up, even in patients who appear clinically stable. Patients should feel encouraged to ask for a cardiology review, particularly if they have recently been in hospital or they are taking diuretics.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Ireland probes mistreatment at care homes run by French company
Representative AI image DUBLIN: Ireland's health ministry Thursday ordered a probe into French care homes operator Emeis, the country's biggest private nursing home provider, after a television programme alleged residents in two places were mistreated. The investigative programme aired undercover footage of elderly residents allegedly forced into chairs, and being ignored when they pleaded for help to go to the toilet. The programme, shown on Irish state broadcaster RTE on Wednesday, also showed some residents were left in incontinence pads for so long their clothes were soaked. The scenes were "extremely distressing" and "wholly unacceptable", health ministry official Kieran O'Donnell told RTE Thursday. The ministry has ordered the Health Information and Quality Authority (HIQA) to launch a review of all nursing homes operated by Emeis, he said. Offering its "sincere apologies", the firm said "this is not the standard of care it expects and not what residents and their families deserve", and pledged to review all operations across Ireland. Emeis, which was called Orpea until last year, run 27 private nursing homes in Ireland. The company entered the Irish market in 2020 through the takeover of another portfolio. HIQA, who are tasked with inspecting care homes, said Emeis-run homes including the two featured in Wednesday's programme had triggered recent concerns. Earlier this year, HIQA ordered one of them to cease admitting new residents, citing "significant concerns". Minister for Enterprise Peter Burke told RTE an institution should not be operating "if people are not being cared for appropriately, with dignity, with respect". "HIQA need to really enforce that and to ensure that everyone has a basic level of dignity and care that they deserve in their twilight years," said Burke. Emeis changed its name to turn the page on a scandal in France when its homes came under scrutiny following the 2022 publication of the book "The Gravediggers" by independent journalist Victor Castan. It cited employees and relatives claiming that residents were at times left for hours with soiled underwear or went days without care as managers sought to maximise profit margins. Orpea contested those claims as "untruthful, scandalous and injurious".
Business Standard
2 days ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
India.com
2 days ago
- India.com
2,000 KM To Gaza: How Greta Thunbergs Aid Ship Became Israels Headache?
A ship transporting humanitarian supplies to Gaza has captured international attention and escalating controversy. The Madleen is the name of the ship belonging to the Freedom Flotilla Coalition (FFC) — an international human rights movement seeking to challenge the Israeli sea blockade of Gaza. This mission becomes even more high-profile with 22-year-old Swedish climate activist Greta Thunberg aboard. Mission With A Message Setting sail from Sicily's port of departure on June 1, the Madleen is attempting a 2,000-kilometer journey to the Gaza Strip. The vessel carried symbolic but essential humanitarian aid, such as flour, milk, water, medicines, baby diapers, and sanitary pads, aimed at the blockaded people in Gaza, where hunger and medical shortages have become critical. Named after Gaza's first and sole female fisherwoman, The Madleen is due to arrive by June 7 — provided it's not blocked by the Israeli navy, which has taken grave concerns about the mission. Greta Thunberg And International Activists Onboard Alongside Greta Thunberg, 11 other international human rights activists are onboard. These include: Rima Hassan – French MP Yasmine Jahr – Germany Baptiste André – France Thiago Ávila – Brazil Omar Fayad, Pascal, and Yanis Mahdi – France Suyab Ordu – Türkiye Sergio Toribio – Spain Marco van Rens – Netherlands Reva Viard – France The coalition sought to challenge peacefully what it calls Israel's illegal blockade and raise international awareness of the Gaza humanitarian crisis. Israel On Alert The Israeli army has publicly said it is keeping an eye on the development closely. Spokeswoman Efi Defrin threatened that Israel will act "according to the circumstances," which indicates that interception is very likely. This comes on the heels of a precedent established last month, when another FFC ship — the Conscience — was allegedly blown up by an Israeli drone attack on May 2. Greta Thunberg Speaks Out Speaking on the ship, Thunberg has stood up for the mission: "We are doing this because we must stand up against injustice. The moment we stop trying, we lose our humanity." Her involvement has, however, triggered intense responses on social media. Photographs and videos of Thunberg waving the Palestinian flag and shouting slogans in support of Gaza have spread on social media, triggering both commendation and reproach. A Symbolic Act Against A 17-Year Blockade Ever since 2007, Israel has maintained a naval blockade on Gaza, managing the import and export of goods and individuals. The Freedom Flotilla Coalition views their mission as a symbolic act of defiance of this blockade, which Israel has determined is both lawful and necessary to ensure national security. As The Madleen approaches Gaza, the world is watching — not so much to witness whether aid finds its way to those most in need, but to see how far activists, governments, and militaries will push each other in the battle for humanitarian access and geopolitical sway.
